Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop.
Aging
/ physiology
Biomarkers
Brain
/ physiopathology
Cerebrovascular Disorders
/ physiopathology
Cognitive Dysfunction
/ physiopathology
Dementia, Vascular
/ physiopathology
Education
Humans
National Heart, Lung, and Blood Institute (U.S.)
National Institute of Neurological Disorders and Stroke (U.S.)
United States
Alzheimer's disease-related dementias
cerebrovascular and cardiovascular disease
vascular contributions to cognitive impairment and dementia
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
06
03
2020
revised:
30
06
2020
accepted:
30
06
2020
pubmed:
9
10
2020
medline:
12
11
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
Vascular contributions to cognitive impairment and dementia (VCID) are characterized by the aging neurovascular unit being confronted with and failing to cope with biological insults due to systemic and cerebral vascular disease, proteinopathy including Alzheimer's biology, metabolic disease, or immune response, resulting in cognitive decline. This report summarizes the discussion and recommendations from a working group convened by the National Heart, Lung, and Blood Institute and the National Institute of Neurological Disorders and Stroke to evaluate the state of the field in VCID research, identify research priorities, and foster collaborations. As discussed in this report, advances in understanding the biological mechanisms of VCID across the wide spectrum of pathologies, chronic systemic comorbidities, and other risk factors may lead to potential prevention and new treatment strategies to decrease the burden of dementia. Better understanding of the social determinants of health that affect risks for both vascular disease and VCID could provide insight into strategies to reduce racial and ethnic disparities in VCID.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1714-1733Subventions
Organisme : NIA NIH HHS
ID : P30 AG049638
Pays : United States
Informations de copyright
© 2020 the Alzheimer's Association.
Références
Gorelick P, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42:2672-2713.
Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2015;11:710-717.
Corriveau RA, Bosetti F, Emr M, et al. The science of vascular contributions to cognitive impairment and dementia (VCID): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol Neurobiol. 2016;36:281-288.
Dementia NWGVCtCIa. NHLBI Working Group Vascular Contributions to Cognitive Impairment and Dementia-Executive Summary. 2018.
Corriveau RA, Koroshetz WJ, Gladman JT, et al. Alzheimer's disease-related dementias summit 2016: national research priorities. Neurology. 2017;89:2381-2391.
Dodge HH, Zhu J, Woltjer R, et al. Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease. Alzheimers Dement. 2017;13:613-623.
Xie W, Zheng F, Yan L, Zhong B. Cognitive decline before and after incident coronary events. J Am Coll Cardiol. 2019;73:3041-3050.
Levine DA, Galecki AT, Langa KM, et al. Trajectory of cognitive decline after incident stroke. JAMA. 2015;314:41-51.
Rawlings AM, Sharrett AR, Schneider AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 2014;161:785-793.
Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol. 2009;66:324-328.
Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057-1064.
Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van Gool WA. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. Alzheimers Res Ther. 2012;4:15.
Singh-Manoux A, Dugravot A, Brunner E, et al. Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology. 2014;83:486-493.
Yu J, Feng Q, Yu J, Zeng Y, Feng L. Late-life cognitive trajectories and their associated lifestyle factors. J Alzheimers Dis. 2020;73:1555-1563.
Deal JA, Power MC, Palta P, et al. Relationship of cigarette smoking and time of quitting with incident dementia and cognitive decline. J Am Geriatr Soc. 2020;68:337-345.
Zuelsdorff M, Okonkwo OC, Norton D, et al. Stressful life events and racial disparities in cognition among middle-aged and older adults. J Alzheimers Dis. 2020;73:671-682.
Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol. 2017;74:1246-1254.
Thacker EL, McKnight B, Psaty BM, et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology. 2013;81:119-125.
Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68:e67-e94.
Rensma SP, Stehouwer CDA, Van Boxtel MPJ, et al. Associations of arterial stiffness with cognitive performance, and the role of microvascular dysfunction: the Maastricht study. Hypertension. 2020;75:1607-1614.
Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation. 2011;123:858-865.
Callisaya ML, Beare R, Moran C, Phan T, Wang W, Srikanth VK. Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study. Diabetologia. 2019;62:448-458.
Gottesman RF, Schneider AL, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443-1450.
Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:57-62.
Lane CA, Barnes J, Nicholas JM, et al. Associations between vascular risk across adulthood and brain pathology in late life: evidence from a British birth cohort. JAMA Neurol. 2019;77:1-9.
Dregan A, Stewart R, Gulliford MC. Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age Ageing. 2013;42:338-345.
Kaffashian S, Dugravot A, Brunner EJ, et al. Midlife stroke risk and cognitive decline: a 10-year follow-up of the Whitehall II cohort study. Alzheimers Dement. 2013;9:572-579.
Joosten H, van Eersel ME, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ. Cardiovascular risk profile and cognitive function in young, middle-aged, and elderly subjects. Stroke. 2013;44:1543-1549.
Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmer RA. Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement. 2014;10:562-570.
Virta JJ, Heikkilä K, Perola M, et al. Midlife cardiovascular risk factors and late cognitive impairment. Eur J Epidemiol. 2013;28:405-416.
Swan G, DeCarli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51:986-993.
Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330:1360.
Kivipelto M, Helkala E-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
Freitag Michael H, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia. Stroke. 2006;37:33-37.
Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55.
Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham heart study. N Engl J Med. 2016;374:523-532.
Wu Y-T, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15:116-124.
Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement. 2019;15:17-24.
Group TSMIftSR. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553-561. PMID:30688979
Group TSMIftSR. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA. 2019;322:524-534. PMID:31408137
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255-2263.
Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M. Multidomain interventions to prevent cognitive impairment, Alzheimer's disease, and dementia: from FINGER to world-wide FINGERS. J Prev Alzheimers Dis. 2020;7:29-36.
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204.
Hachinski V, Einhäupl K, Ganten D, et al. Preventing dementia by preventing stroke: the Berlin Manifesto. Alzheimers Dement. 2019;15:961-984.
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844-866.
Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an update on hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, Alzheimer's Disease Neuroimaging I. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun. 2016;7:11934.
Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99:21-78.
Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21:1318-1331.
Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction-The disregarded partner of Alzheimer's disease. Alzheimers Dement. 2019;15:158-167.
Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270-276.
Montagne A, Barnes Samuel R, Sweeney Melanie D, et al. Blood-Brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296-302.
Iturria-Medina Y, Carbonell FM, Sotero RC, Chouinard-Decorte F, Evans AC. Multifactorial causal model of brain (dis)organization and therapeutic intervention: application to Alzheimer's disease. Neuroimage. 2017;152:60-77.
Dumitrascu OM, Qureshi TA. Retinal vascular imaging in vascular cognitive impairment: current and future perspectives. J Exp Neurosci. 2018;12:1179069518801291.
Hainsworth AH, Allan SM, Boltze J, et al. Translational models for vascular cognitive impairment: a review including larger species. BMC Med. 2017;15:16.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373.
Houston DS, Vanhoutte PM. Serotonin and the vascular system. Drugs. 1986;31:149-163.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci. 1987;84:9265-9269.
Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524.
Vanhoutte PM, Zhao Y, Xu A, Leung S. Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res. 2016;119:375-396.
Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res. 2010;107:1498-1502.
Kwak Y-D, Wang R, Li JJ, Zhang Y-W, Xu H, Liao F-F. Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener. 2011;6:17.
Wang R, Li JJ, Diao S, et al. Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons. Cell Metab. 2013;17:685-694.
Austin SA, Santhanam AV, Hinton DJ, Choi D-S, Katusic ZS. Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. J Neurochem. 2013;127:691-700.
Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. Eur Heart J. 2014;35:888-894.
Austin SA, Katusic ZS. Loss of endothelial nitric oxide synthase promotes p25 generation and tau phosphorylation in a murine model of Alzheimer's disease. Circ Res. 2016;119:1128-1134.
Brix B, Mesters JR, Pellerin L, Jöhren O. Endothelial cell-derived nitric oxide enhances aerobic glycolysis in astrocytes via HIF-1α-mediated target gene activation. J Neurosci. 2012;32:9727-9735.
Faraco G, Brea D, Garcia-Bonilla L, et al. Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response. Nat Neurosci. 2018;21:240-249.
Faraco G, Hochrainer K, Segarra SG, et al. Dietary salt promotes cognitive impairment through tau phosphorylation. Nature. 2019;574:686-690.
Tan X-L, Xue Y-Q, Ma T, et al. Partial eNOS deficiency causes spontaneous thrombotic cerebral infarction, amyloid angiopathy and cognitive impairment. Mol Neurodegener. 2015;10:24.
Austin SA, Katusic ZS. Partial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid. J Cereb Blood Flow Metab. 2020;40:392-403.
Muqtadar H, Testai FD, Gorelick PB. The dementia of cardiac disease. Curr Cardiol Rep. 2012;14:732-740.
Emdin CA, Khera AV, Klarin D, et al. Phenotypic consequences of a genetic predisposition to enhanced nitric oxide signaling. Circulation. 2018;137:222-232.
Katusic ZS, Austin SA. Neurovascular protective function of endothelial nitric oxide- recent advances. Circ J. 2016;80:1499-1503.
Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19:771.
Kisler K, Nelson AR, Rege SV, et al. Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci. 2017;20:406.
Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409-427.
Nikolakopoulou AM, Montagne A, Kisler K, et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci. 2019;22:1089-1098.
Nortley R, Korte N, Izquierdo P, et al. Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes. Science. 2019;365:eaav9518.
Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71-76.
Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512-516.
Faraco G, Sugiyama Y, Lane D, et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest. 2016;126:4674-4689.
Park L, Uekawa K, Garcia-Bonilla L, et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer Aβ peptides. Circ Res. 2017;121:258-269.
Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circ Res. 2019;124:1025-1044.
Srikanth V, Arvanitakis Z, Type 2 Diabetes and Dementia. London: Academic Press; 2018.
Montine TJ, Koroshetz WJ, Babcock D, et al. Recommendations of the Alzheimer's disease-related dementias conference. Neurology. 2014;83:851-860.
Hughes TM, Wagenknecht LE, Craft S, et al. Arterial stiffness and dementia pathology. Atherosclerosis Risk in Communities (ARIC)-PET Study. Neurology. 2018;90:e1248-e1256.
Gottesman RF, Schneider ALC, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443-1450.
Wiesmann M, Roelofs M, van der Lugt R, Heerschap A, Kiliaan AJ, Claassen JA. Angiotensin II, hypertension and angiotensin II receptor antagonism: roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease. J Cereb Blood Flow Metab. 2017;37:2396-2413.
DLKd Jong, RAAd Heus, Rijpma A, et al. Effects of nilvadipine on cerebral blood flow in patients with Alzheimer disease. Hypertension. 2019;74:413-420.
Wiesmann M, Kiliaan AJ, Claassen JAHR. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab. 2013;33:1696-1706.
Kehoe P, Passmore P. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012;30:S251-S68.
Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. PLoS One. 2018;13:e0206705.
Faraco G, Park L, Zhou P, et al. Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab. 2016;36:241-252.
Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19:61-70.
Peters R, Yasar S, Anderson CS, et al. Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology. 2020;94:e267-e281.
Bernstein KE, Khan Z, Giani JF, Cao D-Y, Bernstein EA, Shen XZ. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 2018;14:325.
Bernstein KE, Koronyo Y, Salumbides BC, et al. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. J Clin Invest. 2014;124:1000-1012.
Satizabal C, Beiser AS, Seshadri S. Incidence of dementia over three decades in the framingham heart study. N Engl J Med. 2016;375:92-94.
Pase MP, Satizabal CL, Seshadri S. Role of improved vascular health in the declining incidence of dementia. Stroke. 2017;48:2013-2020.
Seshadri S. Indexes of subclinical atherosclerosis: signposts on the highway to disease. JACC Cardiovasc Imaging. 2014;7:1116-1118.
Dearborn JL, Zhang Y, Qiao Y, et al. Intracranial atherosclerosis and dementia: the Atherosclerosis Risk in Communities (ARIC) study. Neurology. 2017;88:1556-1563.
Baradaran H, Demissie S, Himali JJ, et al. The progression of carotid atherosclerosis and imaging markers of dementia. Alzheimers Dement. 2020;6:e12015.
Khan MMH, Fujiyoshi A, Shiino A, et al. The association between coronary artery calcification and subclinical cerebrovascular diseases in men: an observational study. J Atheroscler Thromb. 2020.
Gustavsson AM, van Westen D, Stomrud E, Engström G, Nägga K, Hansson O. Midlife atherosclerosis and development of alzheimer or vascular dementia. Ann Neurol. 2020;87:52-62.
Maillard P, Mitchell GF, Himali JJ, et al. Aortic stiffness, increased white matter free water, and altered microstructural integrity: a continuum of injury. Stroke. 2017;48:1567-1573.
Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012;11:1039-1047.
Pase MP, Davis-Plourde K, Himali JJ, et al. Vascular risk at younger ages most strongly associates with current and future brain volume. Neurology. 2018;91:e1479-e86.
Weinstein G, Maillard P, Himali JJ, et al. Glucose indices are associated with cognitive and structural brain measures in young adults. Neurology. 2015;84:2329-2337.
Suri MFK, Zhou J, Qiao Y, et al. Cognitive impairment and intracranial atherosclerotic stenosis in general population. Neurology. 2018;90:e1240-e1247.
Cooper LL, Himali JJ, Torjesen A, et al. Inter-relations of orthostatic blood pressure change, aortic stiffness, and brain structure and function in young adults. J Am Heart Assoc. 2017;6:e006206.
Pase MP, Beiser A, Himali JJ, et al. Aortic stiffness and the risk of incident mild cognitive impairment and dementia. Stroke. 2016;47:2256-2261.
Tsao CW, Himali JJ, Beiser AS, et al. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:619-626.
Romero JR, Beiser A, Seshadri S, et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke. 2009;40:1590-1596.
Hoth KF, Poppas A, Moser DJ, Paul RH, Cohen RA. Cardiac dysfunction and cognition in older adults with heart failure. Cogn Behav Neurol. 2008;21:65-72.
Jefferson AL, Beiser AS, Himali JJ, et al. Low cardiac index is associated with incident dementia and Alzheimer disease: the Framingham Heart Study. Circulation. 2015;131:1333-1339.
Merkler AE, Sigurdsson S, Eiriksdottir G, et al. Association between unrecognized myocardial infarction and cerebral infarction on magnetic resonance imaging. JAMA Neurol. 2019;76:956-961.
Pase MP, Beiser A, Enserro D, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke. 2016;47:1201-1206.
Reis JP, Loria CM, Launer LJ, et al. Cardiovascular health through young adulthood and cognitive functioning in midlife. Ann Neurol. 2013;73:170-179.
Roher AE, Esh C, Kokjohn TA, et al. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol. 2003;23:2055-2062.
Gottesman RF, Mosley TH, Knopman DS, et al. Association of intracranial atherosclerotic disease with brain β-amyloid deposition: secondary analysis of the ARIC study. JAMA Neurol. 2019;77:350-357.
McGrath ER, Beiser AS, DeCarli C, et al. Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2017;89:2447-2454.
Spartano NL, Himali JJ, Beiser AS, et al. Midlife exercise blood pressure, heart rate, and fitness relate to brain volume 2 decades later. Neurology. 2016;86:1313-1319.
Bangen KJ, Beiser A, Delano-Wood L, et al. APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis. 2013;22:1361-1369.
Bangen KJ, Himali JJ, Beiser AS, et al. Interaction between midlife blood glucose and APOE genotype predicts later Alzheimer's disease pathology. J Alzheimers Dis. 2016;53:1553-1562.
Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537-547.
Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74:70-76.
Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50:202-211.
Roberts RO, Knopman DS, Przybelski SA, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology. 2014;82:1132-1141.
Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237-2242.
Spauwen PJJ, Köhler S, Verhey FRJ, Stehouwer CDA, van Boxtel MPJ. Effects of type 2 diabetes on 12-year cognitive change. Results from the Maastricht aging study. Diabetes Care. 2013;36:1554-1561.
Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol. 2012;69:1170-1175.
Stoeckel L, Arvanitakis Z, Gandy S, et al. Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Res. 2016;5:353.
Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med. 2014;55:759-764.
Tomita N, Furukawa K, Okamura N, et al. Brain accumulation of amyloid beta protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus. Geriatr Gerontol Int. 2013;13:215-221.
Marchi N, Bazarian JJ, Puvenna V, et al. Consequences of repeated blood-brain barrier disruption in football players. PLoS One. 2013;8:e56805.
Weissberg I, Veksler R, Kamintsky L, et al. Imaging blood-brain barrier dysfunction in football players. JAMA Neurol. 2014;71:1453-1455.
Yoo R-E, Choi SH, Oh B-M, et al. Quantitative dynamic contrast-enhanced MR imaging shows widespread blood-brain barrier disruption in mild traumatic brain injury patients with post-concussion syndrome. Eur Radiol. 2019;29:1308-1317.
Johnson VE, Weber MT, Xiao R, et al. Mechanical disruption of the blood-brain barrier following experimental concussion. Acta Neuropathol. 2018;135:711-726.
Tagge CA, Fisher AM, Minaeva OV, et al. Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain. 2018;141:422-458.
Lee JB, Affeldt BM, Gamboa Y, et al. Repeated pediatric concussions evoke long-term oligodendrocyte and white matter microstructural dysregulation distant from the injury. Dev Neurosci. 2018;40:358-375.
Wendel KM, Lee JB, Affeldt BM, et al. Corpus callosum vasculature predicts white matter microstructure abnormalities after pediatric mild traumatic brain injury. J Neurotrauma. 2018;36(1):152-164.
McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68:709-735.
McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136:43-64.
McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131:75-86.
Stein TD, Montenigro PH, Alvarez VE, et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 2015;130:21-34.
Standring OJ, Friedberg J, Tripodis Y, et al. Contact sport participation and chronic traumatic encephalopathy are associated with altered severity and distribution of cerebral amyloid angiopathy. Acta Neuropathol. 2019;138:401-413.
Doherty CP, O'Keefe E, Wallace E, et al. Blood-brain barrier dysfunction as a hallmark pathology in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2016;75:656-662.
Glushakova OY, Johnson D, Hayes RL. Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood-brain barrier disruption, and progressive white matter damage. J Neurotrauma. 2014;31:1180-1193.
Hay JR, Johnson VE, Young AMH, Smith DH, Stewart W. Blood-brain barrier disruption is an early event that may persist for many years after traumatic brain injury in humans. J Neuropathol Exp Neurol. 2015;74:1147-1157.
Cherry JD, Tripodis Y, Alvarez VE, et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun. 2016;4:112.
Iliff JJ, Chen MJ, Plog BA, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci. 2014;34:16180-16193.
Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17:1016-1024.
Helman AM, Murphy MP. Vascular cognitive impairment: modeling a critical neurologic disease in vitro and in vivo. Biochim Biophys Acta. 2016;1862:975-982.
Santos CY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement. 2017;7:69-87.
de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184-190.
Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol. 2010;223:422-431.
Cifuentes D, Poittevin M, Dere E, et al. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension. 2015;65:218-224.
Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D. Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimers disease. Curr Alzheimer Res. 2010;7:140-149.
Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Aβ generation by altering β- and γ-cleavage of APP. Neurobiol Aging. 2009;30:1091-1098.
Masashi K, Rodrigo M, Frank ML. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des. 2012;18:1131-1147.
Dolmetsch R, Geschwind Daniel H. The human brain in a dish: the promise of iPSC-derived neurons. Cell. 2011;145:831-834.
Canfield SG, Stebbins MJ, Morales BS, et al. An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. J Neurochem. 2017;140:874-888.
Robert J, Button EB, Yuen B, et al. Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. eLife. 2017;6:e29595.
Robert J, Button EB, Stukas S, et al. High-density lipoproteins suppress Aβ-induced PBMC adhesion to human endothelial cells in bioengineered vessels and in monoculture. Mol Neurodegener. 2017;12:60.
Ganguli M, Albanese E, Seshadri S, et al. Population neuroscience: dementia epidemiology serving precision medicine and population health. Alzheimer Dis Assoc Disord. 2018;32:1-9.
Gorelick PB, Furie KL, Iadecola C, et al. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. Stroke. 2017;48:e284-e303.
Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017;49:1373-1384.
Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol. 2007;62:59-66.
Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62:1148-1155.
Dichgans M, Wardlaw J, Smith E, et al. METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: an initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimers Dement. 2016;12:1235-1249.
Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68:e67-e94.
Debette S, Seshadri S. Vascular risk factors and dementia revisited. J Neurol Neurosurg Psychiatry. 2009;80:1183-1184.
Duering M, Gesierich B, Seiler S, et al. Strategic white matter tracts for processing speed deficits in age-related small vessel disease. Neurology. 2014;82:1946-1950.
Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11:157.
Mossa-Basha M, Hwang WD, Havenon AD, et al. Multicontrast high-resolution vessel wall magnetic resonance imaging and its value in differentiating intracranial vasculopathic processes. Stroke. 2015;46:1567-1573.
Chen L, Mossa-Basha M, Balu N, et al. Development of a quantitative intracranial vascular features extraction tool on 3D MRA using semiautomated open-curve active contour vessel tracing. Magn Reson Med. 2018;79:3229-3238.
Rivera-Rivera LA, Turski P, Johnson KM, et al. 4D flow MRI for intracranial hemodynamics assessment in Alzheimer's disease. J Cereb Blood Flow Metabol. 2016;36:1718-1730.
Greenberg SM, William M. Feinberg award for excellence in clinical stroke: big pictures and small vessels. Stroke. 2017;48:2628-2631.
Westover MB, Bianchi MT, Yang C, Schneider JA, Greenberg SM. Estimating cerebral microinfarct burden from autopsy samples. Neurology. 2013;80:1365-1369.
Ferro DA, Mutsaerts HJ, Hilal S, et al. Cortical microinfarcts in memory clinic patients are associated with reduced cerebral perfusion. J Cereb Blood Flow Metab. 2019;0. 0271678×19877403. https://journals.sagepub.com/doi/10.1177/0271678X19877403.
Ferro D, Heinen R, de Brito Robalo B, Kuijf H, Biessels GJ, Reijmer Y. Cortical microinfarcts and white matter connectivity in memory clinic patients. Front Neurol. 2019;10.
Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 2016;15:934-943.
Power MC, Mormino E, Soldan A, et al. Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol. 2018;84:10-22.
Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: jACC scientific expert panel. J Am Coll Cardiol. 2019;73:3326-3344.
Hase Y, Horsburgh K, Ihara M, Kalaria RN. White matter degeneration in vascular and other ageing-related dementias. J Neurochem. 2018;144:617-633.
Howard AC, Julie AS, David AB, Sue L, Steven RL. Associations of cerebrovascular and Alzheimer's disease pathology with brain atrophy. Curr Alzheimer Res. 2014;11:309-316.
Kapasi A, Leurgans SE, James BD, et al. Watershed microinfarct pathology and cognition in older persons. Neurobiol Aging. 2018;70:10-17.
Graff-Radford J, Raman MR, Rabinstein AA, et al. Association between microinfarcts and blood pressure trajectories. JAMA Neurol. 2018;75:212-218.
Lamar M, León A, Romo K, et al. The Independent and Interactive Associations of Bilingualism and Sex on Cognitive Performance in Hispanics/Latinos of the Hispanic Community Health Study/Study of Latinos. J Alzheimers Dis. 2019;71:1271-1283.
Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider JA. The relationship of cerebral vessel pathology to brain microinfarcts. Brain Pathol. 2017;27:77-85.
Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83:74-83.
Blom S, Paavolainen L, Bychkov D, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep. 2017;7:15580.
Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28:206-218.
Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Fifth Edition. 2013. Washington DC: American Psychiatric Association Publishing.
Ghafar M, Miptah HN, O'Caoimh R. Cognitive screening instruments to identify vascular cognitive impairment: a systematic review. Int J Geriatr Psychiatry. 2019;34:1114-1127.
Botha H, Mantyh WG, Graff-Radford J, et al. Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology. 2018;90:e940-e6.
Mathis CA, Kuller LH, Klunk WE, et al. In vivo assessment of amyloid-β deposition in non-demented very elderly subjects. Ann Neurol. 2013;73:751-761.
Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562.
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838.
Langbaum JBS, Chen K, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012;33:827.e11-.e19.
Toledo JB, Toledo E, Weiner MW, et al. Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2012;8:483-489.
Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013;70:600-606.
Nation DA, Edmonds EC, Bangen KJ, et al. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol. 2015;72:546-553.
Arvanitakis Z, Capuano AW, Lamar M, et al. Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology. Neurology. 2018;91:e517-e25.
Hughes TM, Kuller LH, Barinas-Mitchell EJM, et al. Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology. 2013;81:1711-1718.
Hughes TM, Kuller LH, Barinas-Mitchell EJM, et al. Arterial stiffness and β-amyloid progression in nondemented elderly adults. JAMA Neurol. 2014;71:562-568.
Goodheart AE, Tamburo E, Minhas D, et al. Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. NeuroImage Clin. 2015;9:479-483.
Rutgers KS, van Remoortere A, van Buchem MA, et al. Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol Aging. 2011;32:1774-1783.
Abrahamson EE, Stehouwer JS, Vazquez AL, et al. Development of a PET radioligand selective for cerebral amyloid angiopathy. Nucl Med Biol. 2020.
Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277-281.
Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-48.
Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes. 2009;58:71-77.
Rawlings AM, Sharrett AR, Schneider ALC, et al. Diabetes in midlife and cognitive change over 20 years: the Atherosclerosis Risk in Communities Neurocognitive Study. Ann Intern Med. 2014;161:785-793.
Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902-1907.
Gottesman RF, Schneider ALC, Albert M, et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol. 2014;71:1218-1227.
Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011;12:e426-e437.
Tolppanen A-M, Ngandu T, Kareholt I, et al. Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. J Alzheimers Dis. 2013;38:201-209.
Fitzpatrick AL, Kuller LH, Lopez OL, et al. Mid- and late-life obesity: risk of dementia in the cardiovascular health cognition study. Arch Neurol. 2009;66:336-342.
Wagner M, Helmer C, Tzourio C, Berr C, Proust-Lima C, Samieri C. Evaluation of the concurrent trajectories of cardiometabolic risk factors in the 14 years before dementia. JAMA Psychiatry. 2018;75:1033-1042.
Weuve J, Tchetgen Tchetgen EJ, Glymour MM, et al. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. Epidemiology. 2012;23:119-128.
Yaffe K, Vittinghoff E, Pletcher MJ, et al. Early adult to midlife cardiovascular risk factors and cognitive function. Circulation. 2014;129:1560-1567.
Reis JP, Launer LJ, Terry JG, Loria CM, et al. Subclinical atherosclerotic calcification and cognitive functioning in middle-aged adults: the CARDIA study. Atherosclerosis. 2013;231;72-77.
Yano Y, Ning H, Allen N, et al. Long-term blood pressure variability throughout young adulthood and cognitive function in midlife: the Coronary Artery Risk Development in Young Adults (CARDIA) Study: blood pressure variability and cognition. Hypertension. 2014;64:983-988.
Yano Y, Ning H, Reis JP, et al. Blood pressure reactivity to psychological stress in young adults and cognition in midlife: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. J Am Heart Assoc. 2016;5:e002718.
Zeki Al Hazzouri A, Elfassy T, Carnethon MR, Lloyd-Jones DM, Yaffe K. Heart rate variability and cognitive function in middle-age adults: the coronary artery risk development in young adults. Am J Hypertens. 2018;31:27-34.
Al Hazzouri AZ, Vittinghoff E, Sidney S, Reis JP, Jacobs DR, Yaffe K. Intima media thickness and cognitive function in stroke-free middle-aged adults: findings from the CARDIA study. Stroke. 2015;46:2190-2196.
Rovio SP, Pahkala K, Nevalainen J, et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the young finns study. J Am Coll Cardiol. 2017;69:2279-2289.
Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723-738.
Power MC, Adar SD, Yanosky JD, Weuve J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: a systematic review of epidemiologic research. Neurotoxicology. 2016;56:235-253.
Alzheimer's Association. The Healthy Brain Initiative: The Public Health Road Map for State and National Partnerships, 2013-2018. Chicago, IL: Alzheimer's Association; 2013.
Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302-2309.
Haroutunian V, Schnaider-Beeri M, Schmeidler J, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008;65:1211-1217.
Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174:324-333.
Khachaturian ZS, Kuller LH, Khachaturian AS. Strategic goals and roadmap for dementia prevention by stroke prevention. Alzheimers Dement. 2019;15:865-869.